Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

NCT07011849 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants

Conditions

Renal Cell Carcinoma
Brain Metastasis

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]